Estudio piloto comparativo de dos soluciones de sellado en catéteres de hemodiálisis: heparina sódica al 5 por ciento frente a fibrilin® / Comparative pilot study of two haemodialysis catheter lock solutions: 5 percent heparin sodium compared to fibrilin®

El sellado de catéteres en hemodiálisis suele ser motivo de controversia entre los distintos profesionales dedicados a la hemodiálisis. El objetivo del presente estudio es comparar dos soluciones de sellado de catéter para hemodiálisis: heparina al 5% y fibrilin (heparina 20ui/ml + metil y propilparaben). Estudiamos 8 pacientes (mujeres) de 69±12 años portadoras de catéter tunelizado de 17±7 meses de duración del catéter, estables y que habían dado su consentimiento para el estudio. Inicialmente se selló con fibrilin durante un mes (12 sesiones) y posteriormente con heparina al 5% el mismo periodo de tiempo. Se registró velocidad de bomba, flujo efectivo, presión venosa, KT, necesidad de utilizar fibrinolíticos, infecciones, nº de manipulaciones, hipotensiones, recirculación, KT/V, TP, TPTA. Se compararon los estudios mediante t student. Después de dos meses de estudio se observó mayor flujo efectivo 318±23 ml/m en catéteres sellados con heparina frente a 307±17 ml/m con fibrilin (p= 0,008), menor presión venosa 147±12 mm Hg en heparina frente a 168±17 en fibrilin (p=0,006), mayor KT en heparina 43±3 litros frente a 41±4 litros en fibrilin. A pesar de estas mejores condiciones, clínicamente no supusieron diferencias en la eficacia dialítica KT/V heparina 1,56±0,2 frente a 1,59 ±0,2 en fibrilin. Si se observó un mayor nº de manipulaciones del catéter en heparina 12±0,2 frente a 9,4±1,3 en fibrilin (p=0,001). No existieron diferencias en aparición de infecciones, recirculación, necesidad de fi brinoliticos o alteraciones de coagulación. Concluimos que el sellado de catéteres de Hemodiálisis con Fibrilin es una alternativa eficaz a la heparina al 5%. No se acompaña de un mayor grado de disfunción del catéter y si de un menor nº de manipulaciones, lo que podría condicionar un menor nº de infecciones asociado a catéteres(AU)

Catheter locks in haemodialysis are usually a source of controversy among the different professionals involved in haemodialysis. The aim of this study is to compare two haemodialysis catheter lock solutions: 5% heparin and fibrilin (heparin 20ui/ml + methyl and propyl paraben). We studied 8 patients (women) aged 69±12 years with tunnelled catheters of 17±7 months’ duration, whose condition was stable and who had given their consent to the study. Initially, the fibrilin lock solution was used with the catheters for one month (12 sessions) and then 5% heparin for the same length of time. Pump speed, effective flow, venous pressure, KT, the need to use fibrinolytics, infections, number of handlings, hypotension episodes, recirculation, KT/V, TP, TPTA were measured. The results were compared using student’s t-test. After two months of study, a greater effective flow 318±23 ml/m was observed in catheters with heparin lock compared to 307±17 ml/m with fibrilin (p= 0.008), lower venous pressure 147±12 mm Hg in heparin compared to 168±17 in fibrilin (p=0,006), higher KT in heparin 43±3 litres compared to 41±4 litres in fibrilin. Despite these better conditions, they did not represent clinical differences in dialysis efficacy, KT/V heparin 1.56±0.2 compared to 1.59 ±0.2 in fibrilin. A higher number of catheter handlings was observed in heparin 12±0.2 compared to 9.4±1.3 in fibrilin (p=0.001). There were no differences in the appearance of infections, recirculation, need for fi brinolytics or coagulation alterations. We conclude that the use of fibrilin lock solution for haemodialysis catheters is an effective alternative to 5% heparin. It is not accompanied by a higher degree of catheter dysfunction but does involve less handling, which could lead to fewer catheter-associated infections(AU)

[Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis]. / Einfluss neuer Dialysatlösungen auf klinische Ergebnisse bei Peritonealdialyse-Patienten.

Long-term peritoneal dialysis is associated with changes in the peritoneal membrane. Conventional dialysate solutions are bioincompatible because of their low pH, high glucose content, hyperosmolality and increased concentration of glucose degradation products. The development of double-compartment systems has made it possible to separate glucose from the buffer during heat sterilization, resulting in a higher or even physiologic pH of the solution with reduced concentration of glucose degradation products. These new solutions are less toxic for several cell groups and are better than conventional solutions in preserving membrane function, as demonstrated by experiments in rats. Glucose degradation products promote formation of advanced glycation end-products, and plasma levels of these are markedly reduced when double-compartment systems are used. Clinical studies with these more physiologic dialysis solutions have demonstrated better correction of acidosis, less inflow pain, significantly elevated CA-125 dialysate levels and lower concentrations of markers for inflammation and fibrosis in the effluent. In a retrospective study, a lower rate of mortality was observed in patients who were treated using a double-compartment system than in those treated with standard dialysis solution. Amino acids (in the low-molecular-weight range) and icodextrin (in the high-molecular-weight range) are newer osmotic agents that have been developed as alternatives to glucose. Several clinical studies have shown that amino-acid solution improves various nutritional parameters in patients with malnutrition and is more biocompatible than standard glucose solution. Icodextrin is an iso-osmolar dialysis solution. Ultrafiltration takes place via colloid osmotic pressure and is sufficient in all types of peritoneal transport. Clinical studies using icodextrin have shown better fluid control, especially in high transporters, reduced carbohydrate load and fewer patients with ultrafiltration failure compared with those treated with conventional dialysis solutions. However, allergic skin reactions have been observed in up to 10% of patients treated with icodextrin. Icodextrin may induce a fall of sodium plasma levels. Because of cross-reaction with elevated plasma levels of maltose, serum amylase is determined falsely low and glucose (using the glucose-dehydrogenase method) is measured falsely high, but high plasma levels of maltose do not affect measurement of lipase or measurement of glucose using the glucose-oxidase method. New dialysate solutions will have a positive influence on both survival and technical drop-out rates in patients receiving peritoneal dialysis treatment.